1. Introduction {#sec1}
===============

Angina is pain or constricting discomfort that typically occurs in the front of the chest and is brought on by physical exertion or emotional stress \[[@B1]\]. It is the main symptomatic manifestation of myocardial ischemia, caused by an imbalance between myocardial blood supply and oxygen demand \[[@B1], [@B2]\]. The prevalence of angina in the population appears to increase in the past decades \[[@B3]\]. A meta-analysis of data from 31 countries indicated the population weighted prevalence was 6.7% in woman and 5.7% in man \[[@B4]\]. Angina is a common initial presentation of coronary disease \[[@B5]\], and it may exert a major impact on quality of life, ability to work, and costs to society \[[@B6], [@B7]\].

Angina is clinically classified into stable angina (SA) and unstable angina (UA), and treatment strategy is different between them. SA is a chronic medical condition and the aim of management for it is to abolish or minimize symptoms, improve quality of life, and decrease long-term morbidity and mortality \[[@B1]\] while UA is an acute coronary syndrome, which should be treated as an emergency \[[@B8]\]. The current antiangina medical management includes pharmacological strategies, revascularization strategies, and lifestyle interventions. Chinese herbal medicine (CHM) is also widely used for treating angina in China \[[@B9]\].

Because angina is a life-threatening event and very effective western medicine treatments are available, CHM is usually used in addition to baseline treatment with western medicine. Common CHM prescribed for treating angina includes Tongxinluo capsules, Fufangdanshen dripping pills, Shengmai capsules, and Shexiangbaoxin tablets. Tongxinluo capsules mainly take effect by dilating coronary arteries, increasing blood vessel perfusion flow, and strengthening cardiac contractility \[[@B10], [@B11]\]. Fufangdanshen dripping pills may alleviate angina via the antimyocardial ischemia and antiatherosclerotic effect \[[@B12], [@B13]\]. Likewise, not only can Shengmai capsules raise coronary blood flow, it may also improve the tissue tolerance to oxygen privation of cardiac muscle \[[@B14]\]. Apart from expanding blood vessel and increasing crown arteries current capacity, Shexiangbaoxin tablets may also alleviate arteriosclerosis and steady plague \[[@B15]\]. However, there is still a knowledge gap to clearly establish evidence that CHM is effective in improving the outcomes of angina patients. We therefore performed this systematic review of randomized controlled trials (RCT) to evaluate the add-on effect of CHM in angina patients.

2. Materials and Methods {#sec2}
========================

This study was undertaken according to the recommendation of Cochrane handbook for systematic reviews of interventions \[[@B16]\] and reported according to the PRISMA statement \[[@B17]\].

2.1. Inclusion Criteria {#sec2.1}
-----------------------

Studies are eligible if (1) RCTs which compared CHM + western medicine versus western medicine, or compared CHM versus no treatment/placebo; (2) the participants were patients with stable or unstable angina (diagnosed by typical angina chest pain, and ischemic ST-segment depression by electrocardiography); (3) the intervention may be any preparations containing at least one herb that is included in the latest version of the Chinese Pharmacopeia; (4) the follow-up time should be at least 7 days. The primary outcome of this study is mortality (death from myocardial infarction (MI) and other causes). The secondary outcomes include recurrent MI, heart failure, quality of life, use of revascularization, deterioration or improvement in symptoms of angina, and adverse events. Trials were eligible if one of the hard outcomes (mortality, recurrent MI, or heart failure) was reported.

2.2. The Literature Search {#sec2.2}
--------------------------

We searched CENTRAL, MEDLINE, EMBASE, CINAHL, AMED, Chinese Biomedical Database (CBM), Chinese Medical Current Contents (CMCC), and Traditional Chinese Medical Literature Analysis and Retrieval System (TCMLARS) since their inception to July 2010 ([Figure 1](#fig1){ref-type="fig"}). There was no limitation on language or publication status. The search strategy included the following key words: "Chinese herbal," "traditional Chinese medicine," "herb," "angina," "stenocardia," "clinical trials," and "randomized controlled trial." The reference lists of relevant trials and review articles, abstracts from major relevant conferences, and relevant trials registers were checked for additional studies.

2.3. Selection of Studies {#sec2.3}
-------------------------

Study eligibility was independently determined by two authors. All the citations were inputted into reference management software Endnote, and the duplicates were removed. The authors then evaluated the eligibility of remaining studies by examining the titles, abstracts, and full articles progressively. Discrepancies were resolved by discussion.

2.4. Data Extraction and Quality Assessment {#sec2.4}
-------------------------------------------

Data were extracted independently by two authors using a standard form. Data extracted include (1) general information (e.g., title, authors, reference, language, year of publication, and setting); (2) trial characteristics related to methodological quality (e.g., design, duration of followup, sequence generation, allocation sequence concealment, and blinding); (3) intervention and comparison (dose, route, and timing); (4) patients (e.g., baseline characteristics and diagnostic criteria); (5) outcomes (e.g., estimates, standard error, and *P* value). Discrepancies were resolved by discussion. The authors of original studies were consulted for missing information where necessary.

The methodological quality of included randomized trials was assessed and reported by the Cochrane Collaboration\'s tool to assess the risk of bias \[[@B16]\]. The methodological quality assessed included: (1) sequence generation, (2) allocation sequence concealment, (3) blinding, (4) incomplete outcome data, (5) selective outcome reporting, and (6) other potential sources of bias.

2.5. Data Analysis {#sec2.5}
------------------

All analyses were conducted using the Review Manager software compiled by the Cochrane Collaboration \[[@B16]\]. Dichotomous outcomes were expressed as relative risk (RR). 95% confidence intervals (CIs) were calculated for all estimates. Tests for heterogeneity were performed with chi-squared test at a significance level of *P* = 0.1. *I* ^2^ statistic was calculated to estimate variation across studies. We regarded *I* ^2^ \< 25% as an indicator of low heterogeneity level, 25--50% as moderate level, and \>50% as high level. The estimates were pooled with a fixed-effect model if there was no significant heterogeneity. Whenever a significant heterogeneity presented, a random-effect model was used to pool the results. We intended to explore the potential sources of heterogeneity by subgroup analysis and metaregression if the number of trials was sufficient. We assessed the publication bias by funnel plot, and adjustment was made to reduce the effect of publication bias in the estimate of effectiveness.

3. Results {#sec3}
==========

3.1. The Literature Search and Study Characteristics {#sec3.1}
----------------------------------------------------

[Figure 1](#fig1){ref-type="fig"} showed the study selection in this study. Our search in bibliographic databases yielded 15866 citations, of which 2660 were classified as potentially relevant and were subjected to full text assessment. Finally, a total of 46 studies were included \[[@B18]--[@B63]\], of which 9 studies included patients with SA \[[@B18]--[@B26]\], 31 studies included patients with UA \[[@B27]--[@B57]\], and 6 studies included patients with SA or UA \[[@B58]--[@B63]\]. This systematic review totally included 4212 patient, with 2141 patients receiving the combination of CHM and western medicine and 2071 patients receiving western medicine alone. The duration of treatment and followup ranged from 1 day to 48 days, and 7 months to 36 months, respectively. [Table 1](#tab1){ref-type="table"} demonstrated the characteristics of included studies.

3.2. Risk of Bias {#sec3.2}
-----------------

Among included studies, only 6 trials concealed allocation sequence, two studies did not conceal the allocation sequence generated, and the rest studies were unclear. As to randomization, two studies had high risk of bias, and the rest studies had either low or uncertain risk of bias. All the included studies had low risk of bias except one study that had high risk of bias for selective outcome reporting. The details are shown in [Table 2](#tab2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}.

3.3. Add-On Effect of Chinese Herbal Medicine in Patients with SA {#sec3.3}
-----------------------------------------------------------------

For trials that only included SA patients, we analyzed the following outcomes: total heart events (3 trials), MI (7 trials), cardiac arrhythmia (2 trials), heart failure (3 trials), angina (6 trials), and death (2 trials). All pooled results showed homogeneity (*P* \> 0.1). Though the SA patients in CHM group had a lower death rate (1.74%) than SA patients in control group (5.22%), the difference was not statistically significant (*P* = 0.190). Twenty-three out of 150 SA patients who were treated with the combination of CHM with western medicine got total heart events, with an incidence rate of 15.33%, which was significantly lower (RR = 0.50, 95% CI 0.33--0.78; *P* = 0.002) than that of SA patients who were treated with western medicine alone (30.61%). Compared with western medicine alone, the combination of CHM with western medicine significantly reduced the occurrence of myocardial infarction, from 6.67% to 1.85, with the pooled RR equal to 0.32 (95% CI 0.14--0.72, *P* = 0.006). The incidences of heart failure (RR = 0.37, 95% CI 0.15--0.91; *P* = 0.031), cardiac arrhythmia (RR = 0.27, 95% CI 0.13--0.57; *P* = 0.001), and angina (RR = 0.46, 95% CI 0.30--0.71; *P* \< 0.001) were also significantly lower in SA patients who were treated with the combination of CHM with western medicine than that of patients treated with western medicine alone. There were only one study that explored the difference of difference on the outcomes of fatal events, sudden cardiac death, and adverse events such as bleeding and stomach discomfort between patients in CHM group and patients in control group, none of them were different between two groups. Visual inspection of the funnel plots revealed no asymmetry except the meta-analysis of the occurrence of angina. Details of statistical results can be found in [Table 3](#tab3){ref-type="table"} and Figures [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and [7](#fig7){ref-type="fig"}.

3.4. Add-On Effect of Chinese Herbal Medicine in Patients with UA {#sec3.4}
-----------------------------------------------------------------

For trials that only included UA patients, we analyzed the following outcomes: total heart events (7 trials), death (1 trial), MI (19 trials), cardiac arrhythmia (1 trial), heart failure (2 trials), angina (12 trials), need for cardiac surgery (2 trials), and need for PCI (3 trials). All pooled results showed homogeneity. There are 337 patients in CHM group, of whom 36 patients developed total heart events (10.68%), while 78 out of 333 patients (23.42%) in the control group occurred total heart events. Patients in CHM group had a significant lower incidence of total heart events than patients in the control group, with a pooled RR equal to 0.46 (95% CI 0.32--0.66, *P* \< 0.001). Compared with western medicine alone, the combination of CHM with western medicine significantly reduced the occurrence of myocardial infarction, from 12.42% in control group to 4.26% in CHM group, with a pooled RR of 0.37 (95% CI 0.26--0.54, *P* \< 0.001). Patients in the CHM group had significant lower heart events (RR = 0.46, 95% CI 0.32--0.66; *P* \< 0.001), myocardial infarction (RR = 0.37, 95% CI 0.26--0.54; *P* \< 0.001), angina (RR = 0.36, 95% CI 0.26--0.51; *P* \< 0.001), and sudden cardiac death (RR = 0.22, 95% CI 0.06--0.84; *P* = 0.027) than patients in control group. Pooled result showed no significant difference on death (RR = 0.19, 95% CI 0.01--3.84; *P* = 0.279), heart failures (RR = 0.41, 95% CI 0.15--1.09; *P* = 0.075) and fatal events (RR = 0.33, 95% CI 0.07--1.62; *P* = 0.173) between groups. Two studies presented the data on the adverse events on the treatment, and there is no significant difference on bleeding and stomach discomfort between groups. Visual inspection of funnel plots suggesting there\'s no publication bias. Details of statistical results can be found in [Table 3](#tab3){ref-type="table"} and Figures [8](#fig8){ref-type="fig"}, [9](#fig9){ref-type="fig"}, [10](#fig10){ref-type="fig"}, [11](#fig11){ref-type="fig"} and [12](#fig12){ref-type="fig"}.

3.5. Add-On Effect of Chinese Herbal Medicine in Patients with SA and UA {#sec3.5}
------------------------------------------------------------------------

For trials including patients with diagnosis of either SA or UA, we analyzed the following outcomes: total heart events (1 trial), MI (4 trials), cardiac arrhythmia (1 trial), heart failure (2 trials), angina (4 trials), need for cardiac surgery (1 trial), and death (2 trials). All pooled results showed homogeneity. Total death rate in CHM group was 3.47% (6/173), compared with 5.44% (11/202) for the control group. The result showed that patients treated with CHM did not have a significant lower death rate than no-CHM treatment patients group, with a pooled RR of 0.58 (95% CI 0.23--1.48; *P* = 0.256). There was no evidence of statistical heterogeneity across the studies using the *I* ^2^ test (*I* ^2^ = 0, *P* = 0.570). Meta-analysis of trials comparing the effect of CHM with no CHM treatment in patients with either SA or UA showed that the myocardial infarction rate was 3.13% (10/320) and 8.91% (31/348) in CHM treatment group and control group, respectively, with a pooled RR of 0.34 (95% CI 0.17--0.68; *P* = 0.002). There was enough evidence to illustrate that patients with CHM treatment had a significant lower myocardial infarction rate than the control group. No evidence of statistical heterogeneity across the studies was identified using the *I* ^2^ test (*I* ^2^ = 0, *P* = 0.984 \> 0.1). Meta-analysis showed that patients with CHM treatment had a significant lower angina rate than no CHM treatment group, with a pooled RR of 0.46 (95% CI 0.30--0.70; *P* = 0.000). There was no evidence of statistical heterogeneity (*I* ^2^ = 0, *P* = 0.874 \> 0.1). Visual inspection of funnel plots suggesting no publication bias. Details of statistical results can be found in [Table 3](#tab3){ref-type="table"} and Figures [13](#fig13){ref-type="fig"}, [14](#fig14){ref-type="fig"}, [15](#fig15){ref-type="fig"} and [16](#fig16){ref-type="fig"}.

4. Discussion {#sec4}
=============

This systematic review synthesized evidence from 4212 patients in 46 RCTs. The main findings of this systematic review are as follows. (1) The combination of CHM with western medicine may significantly reduce the occurrence of total heart events, MI, cardiac arrhythmia, heart failure, and angina compared with western medicine alone in patients with SA. (2) For patients with UA, the combination therapy is superior to western medicine alone on total heart events, myocardial infarction, angina, and sudden cardiac death. But there is no significant difference on the incidence of death, cardiac arrhythmia, hart failure, fatal events, cardiac surgery, and percutaneous coronary intervention. (3) For patients with SA or UA, the combination therapy may lead to significant lower occurrence of myocardial infarction, heart failure, and angina as compared with western medicine monotherapy, but no significant differences were indentified on the incidence of total heart events, death, cardiac arrhythmia, fatal events, sudden cardiac death, cardiac operation, bleeding, and stomach discomfort.

Apart from this study, the add-on benefits of CHM on top in western medicine treatment in angina patients were also studied in some other systematic reviews \[[@B64]\]. It was suggested that Danshen preparation \[[@B65], [@B66]\], Dengzhanhua injection \[[@B67]\], Tongxinluo capsule \[[@B68], [@B69]\], Shuxuetong \[[@B70]\], Ginkgo extract \[[@B71], [@B72]\], and Compound salvia pellet \[[@B73], [@B74]\] would be beneficial for angina patients. These systematic reviews usually only focused on one type of CHM \[[@B15], [@B65]--[@B67], [@B69]--[@B73]\], included only a limited number of original studies \[[@B65], [@B67], [@B70]\], and did not receive update for a long time \[[@B66], [@B67], [@B69]\], and their conclusions may therefore be influenced.

The overall risk of bias of included studies was moderate. Inadequacy in reporting methods for randomization and allocation concealment is a major problem among most included RCTs, which may lead to selection bias in our study \[[@B16]\]. The lack of blinding is another problem in most included trials; however, the impact on conclusion was less critical as we focused on objective outcomes. Visual inspection of funnel plots indicated no symmetry on most outcomes, except for the meta-analysis of angina in patients with SA. We therefore believe publication bias is unlikely to be a serious threat to the estimates.

Apart from the limitations on the quality of included studies, the estimates of some outcomes, such as the incidence of fatal events, sudden cardiac death, and bleeding in patients with UA are also limited by relatively small sample size. For these outcomes, only one study with less than 100 patients was included in meta-analysis, and the precision of estimates was therefore influenced \[[@B75]\].

To the best of our knowledge, this is the most comprehensive assessment of add-on effect of CHM in patients with angina. We employed a contemporaneous search strategy in both international and Chinese databases to ensure most studies were included. This enabled us to locate a much higher number of studies compared to other existing reviews on this topic. Additionally, the study selection, data extraction, and quality assessment in this study were independently carried out by two authors to ensure high validity.

This study has important implication for clinical practice and CHM research. For practitioners, this systematic review demonstrated consistent, add-on benefits of using CHM on top in western medicine treatment for preventing all-cause and cardiac mortality amongst angina patients. However, this conclusion was drawn from moderate or low quality trials and the estimates on some outcomes were based on limited number of patients. Large scale, rigorously designed RCTs are still wanted to confirm these conclusions.

All authors declare that they have no conflict of interests.

Chen Mao and Vincent C. H. Chung are the cofirst authors of this paper.

This study is funded by the Chinese Medicine Department, Hong Kong Hospital Authority (CUHK Project code: 7050098).

![Flowchart of study selection.](ECAM2013-673193.001){#fig1}

![The quality of included studies.](ECAM2013-673193.002){#fig2}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with stable angina: outcome = death.](ECAM2013-673193.003){#fig3}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with stable angina: outcome = total heart events.](ECAM2013-673193.004){#fig4}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with stable angina: outcome = myocardial infarction.](ECAM2013-673193.005){#fig5}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with stable angina: outcome = angina.](ECAM2013-673193.006){#fig6}

![Funnel plot for relative risk of occurrence of angina between traditional Chinese medicine group and control group in patients with stable angina.](ECAM2013-673193.007){#fig7}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with unstable angina: outcome = total heart events.](ECAM2013-673193.008){#fig8}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with unstable angina: outcome = myocardial infarction.](ECAM2013-673193.009){#fig9}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with unstable angina: outcome = heart failure.](ECAM2013-673193.010){#fig10}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with unstable angina: outcome = angina.](ECAM2013-673193.011){#fig11}

![Funnel plot for relative risk of occurrence of angina between traditional Chinese medicine group and control group in patients with unstable angina.](ECAM2013-673193.012){#fig12}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with angina: outcome = death.](ECAM2013-673193.013){#fig13}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with angina: outcome = myocardial infarction.](ECAM2013-673193.014){#fig14}

![Meta-analysis of trials comparing the effect of traditional Chinese medicine with no treatment in patients with angina: outcome = angina.](ECAM2013-673193.015){#fig15}

![Funnel plot for relative risk of occurrence of angina between traditional Chinese medicine group and control group in patients with angina.](ECAM2013-673193.016){#fig16}

###### 

Main characteristic of included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Diagnosis   Patient no.\           Treatment                                            Treatment duration (days)       Followup\   
                                                   intervention/control                                                                                        (months)    
  ------------------------------------ ----------- ---------------------- ---------------------------------------------------- ------------------------------- ----------- -----
  Qi et al \[[@B18]\], 1996            SA          26/20                  Shexiangbaoxin tablets + WM                          WM                              14          NR

  Liu and Gong \[[@B19]\], 2003        SA          38/37                  Shengmai capsules + WM                               WM                              NR          6

  Shen et al. \[[@B20]\], 2003         SA          45/42                  Fufangdanshen dripping pills +                       WM                              NR          36

  Yu et al. \[[@B21]\], 2006           SA          32/33                  Xuezhikang capsules + WM                             WM                              180         6

  Hou \[[@B22]\], 2007                 SA          63/60                  Danhong In + WM                                      WM                              14          1

  Yao et al. \[[@B23]\], 2007          SA          60/60                  Weiaoxin + WM + placebo                              WM + placebo                    30          12

  Gao et al. \[[@B24]\], 2008          SA          40/36                  Yiqihuoxuefang + WM without antiplatelet drug        WM without antiplatelet drug    30          1

  Li \[[@B25]\], 2008                  SA          50/50                  Dengzhanshengmai capsules + WM                       WM                              360         12

  Ye \[[@B26]\], 2009                  SA          55/55                  Xinyuan capsules + Simvastahn                        Simvastahn                      365         12

  Long et al. \[[@B27]\], 2000         UA          23/23                  Tongxinluo capsules + WM                             WM                              NR          NR

  Wu and Cui \[[@B28]\], 2001          UA          20/20                  Shuxuetong In + WM                                   WM                              10          NR

  Xiao et al. \[[@B29]\], 2001         UA          40/38                  Xuezhikang capsules + WM                             WM                              90          3

  Deng \[[@B30]\], 2002                UA          35/22                  Ziniguanxintong decoction + WM                       WM                              58          2

  Yang \[[@B31]\], 2002                UA          75/75                  Ruxinan capsules + WM                                WM                              21          3

  Zhao \[[@B32]\], 2002                UA          23/23                  Xuesaitong pills + WM                                WM                              NR          NR

  Gao et al \[[@B33]\], 2003           UA          33/33                  Xintong oral liquid + WM                             WM                              90          3

  Hong et al \[[@B34]\], 2003          UA          60/60                  Fufangdanshen dripping pills + WM                    WM                              28          6

  Nian \[[@B35]\], 2003                UA          15/15                  Tongxinluo capsules + WM                             WM                              28          1

  Zhang and Hong \[[@B36]\], 2003      UA          50/50                  Fufangdanshen dripping pills + WM                    WM                              28          6

  Chen \[[@B37]\], 2004                UA          30/27                  Shexiangbaoxin pills + WM                            WM                              28          48

  Chen et al. \[[@B38]\], 2005         UA          27/23                  Ciwujia In + WM                                      WM                              14          3

  Peng \[[@B39]\], 2005                UA          46/46                  Shuxuening In + WM + aspirin + dinitrosorbide        WM + aspirin + dinitrosorbide   NR          NR

  Liu and Wang \[[@B40]\], 2006        UA          32/32                  Tongxinluo capsules + WM                             WM                              56          2

  Yuan et al. \[[@B41]\], 2006         UA          46/46                  Shuxuening In + WM                                   WM                              14          6

  Ning et al. \[[@B42]\], 2007         UA          56/56                  Tanshinone II A sulfoacid In + WM                    WM                              14          6

  Ma et al. \[[@B43]\], 2007           UA          30/29                  Tanshinone II A sulfoacid In + WM + dinitrosorbide   WM + dinitrosorbide             14          1

  Xiao \[[@B44]\], 2007                UA          30/28                  Chaihuxianxiong decoction + WM                       WM                              30          6

  Yang et al. \[[@B45]\], 2007         UA          31/31                  Buxuzhuyuheji + WM                                   WM                              14          6

  Cai and Wei \[[@B46]\], 2008         UA          56/56                  Danshendongganfen + WM                               WM                              14          6

  Cai \[[@B47]\], 2008                 UA          56/54                  Gegensu capsules + WM                                WM                              14          2

  Chen and Fan \[[@B48]\], 2008        UA          30/30                  Xintongfang + WM + dinitrosorbide                    WM + dinitrosorbide             28          1

  Liu \[[@B49]\], 2008                 UA          31/31                  Gegensu In + WM                                      WM                              14          3

  Zhang and Chen \[[@B50]\], 2008      UA          45/45                  Tongxinluo capsules + WM                             WM                              NR          1.5

  Cai and Wang \[[@B51]\], 2009        UA          58/50                  Tongxinluo capsules + WM + dinitrosorbide            WM + dinitrosorbide             28          1

  Chen and Ye \[[@B52]\], 2009         UA          50/50                  Dengzhanshengmai capsules+ WM                        WM                              180         6

  Su et al. \[[@B53]\], 2009           UA          60/58                  Danhong In + WM                                      WM                              14          NR

  Wang \[[@B54]\], 2009                UA          44/42                  Gegensu In + WM                                      WM                              14          2

  Wang et al. \[[@B55]\], 2009         UA          37/34                  Shuxuetong In + WM                                   WM                              7           NR

  Yu and Chen \[[@B56]\], 2009         UA          68/30                  Tongxinluo capsules + WM                             WM                              NR          3

  He et al. \[[@B57]\], 2010           UA          54/54                  Yiqiyangyinfang + WM                                 WM                              28          8

  Wu and Li \[[@B58]\], 2005           SA or UA    93/123                 Tongxinluo capsules + WM                             WM                              14          0.5

  Li et al. \[[@B59]\], 2008           SA or UA    136/135                Quyuningxin WM pills + WM                            WM                              14          0.5

  Dong \[[@B60]\], 2008                SA or UA    80/79                  Shexiangbaoxin pills + WM + dinitrosorbide           WM + dinitrosorbide             90          3

  H. Shi and Q. Shi \[[@B61]\], 2009   SA or UA    63/61                  Fufangdanshen dripping pills + WM                    WM                              NR          12

  Shi and Jiang \[[@B62]\], 2009       SA or UA    30/30                  Tongxinluo capsules + WM atorvastatin                WM atorvastatin                 180         6

  Lin and Wu \[[@B63]\], 2010          SA or UA    39/39                  Fufangdanshen dripping pills + WM                    WM                              28          6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SA: stable angina; UA: unstable angina; WM: west medicine; NR: not reported.

###### 

Methodological qualities of the included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Risk of bias\       Risk of bias for concealment   Risk of bias for blinding   Risk of bias for incomplete data   Risk of bias for selective outcome reporting   Risk bias for other problems
                                       for randomization                                                                                                                                                
  ------------------------------------ ------------------- ------------------------------ --------------------------- ---------------------------------- ---------------------------------------------- ------------------------------
  Qi et al \[[@B18]\], 1996            Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Liu and Gong \[[@B19]\], 2003        Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Shen et al. \[[@B20]\], 2003         High risk           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Yu et al. \[[@B21]\], 2006           Low risk            Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Hou \[[@B22]\], 2007                 Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Yao et al. \[[@B23]\], 2007          Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Gao et al. \[[@B24]\], 2008          Low risk            Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Li \[[@B25]\], 2008                  Uncertain           Uncertain                      Low risk                    Low risk                           High risk                                      Low risk

  Ye \[[@B26]\], 2009                  Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Long et al. \[[@B27]\], 2000         Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Wu and Cui \[[@B28]\], 2001          Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Xiao et al. \[[@B29]\], 2001         High risk           Uncertain                      Low risk                    Low risk                           Low risk                                       High risk

  Deng \[[@B30]\], 2002                Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Yang \[[@B31]\], 2002                Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Zhao \[[@B32]\], 2002                Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       High risk

  Gao et al \[[@B33]\], 2003           Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Hong et al \[[@B34]\], 2003          Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       High risk

  Nian \[[@B35]\], 2003                Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Zhang and Hong \[[@B36]\], 2003      Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       High risk

  Chen \[[@B37]\], 2004                Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Chen et al. \[[@B38]\], 2005         Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Peng \[[@B39]\], 2005                Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Liu and Wang \[[@B40]\], 2006        Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Yuan et al. \[[@B41]\], 2006         Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Ning et al. \[[@B42]\], 2007         Low risk            Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Ma et al. \[[@B43]\], 2007           Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Xiao \[[@B44]\], 2007                Low risk            Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Yang et al. \[[@B45]\], 2007         Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Cai and Wei \[[@B46]\], 2008         Low risk            Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Cai \[[@B47]\], 2008                 Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Chen and Fan \[[@B48]\], 2008        Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Liu \[[@B49]\], 2008                 Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Zhang and Chen \[[@B50]\], 2008      Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Cai and Wang \[[@B51]\], 2009        Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Chen and Ye \[[@B52]\], 2009         Uncertain           Uncertain                      Low risk                    High risk                          Low risk                                       Low risk

  Su et al. \[[@B53]\], 2009           Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Wang \[[@B54]\], 2009                Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       High risk

  Wang et al. \[[@B55]\], 2009         Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Yu and Chen \[[@B56]\], 2009         Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  He et al. \[[@B57]\], 2010           Low risk            Low risk                       Low risk                    Low risk                           Low risk                                       Low risk

  Wu and Li \[[@B58]\], 2005           Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Li et al. \[[@B59]\], 2008           Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Dong \[[@B60]\], 2008                Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  H. Shi and Q. Shi \[[@B61]\], 2009   Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Shi and Jiang \[[@B62]\], 2009       Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       Low risk

  Lin and Wu \[[@B63]\], 2010          Uncertain           Uncertain                      Low risk                    Low risk                           Low risk                                       High risk
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Chinese herbal medicine plus western medicine versus western medicine alone for treating stable angina: meta-analysis results.

  Events                             No. of studies   No. of events/total no.   Combined effect   Heterogeneity                                  
  ---------------------------------- ---------------- ------------------------- ----------------- -------------------- --------- ------- ------- ------
  Stable angina                                                                                                                                   
   Total heart events                3                23/150                    45/147            0.50 (0.33--0.78)    0.002     0.39    0.825   0.0
   Death                             2                2/115                     6/115             0.38 (0.09--1.61)    0.190     0.01    0.920   0.0
   Myocardial infarction             7                6/324                     21/315            0.32 (0.14--0.72)    0.006     1.34    0.970   0.0
   Cardiac arrhythmia                2                7/93                      25/92             0.27 (0.13--0.57)    0.001     0.28    0.594   0.0
   Heart failure                     3                6/168                     16/165            0.37 (0.15--0.91)    0.031     0.27    0.875   0.0
   Angina                            6                26/306                    55/298            0.46 (0.30--0.71)    \<0.001   2.75    0.739   0.0
   Fatal events                      1                1/45                      2/42              0.47 (0.04--4.96)    0.527     ---     ---     ---
   Sudden cardiac death              1                2/50                      3/50              0.67 (0.12--3.82)    0.649     ---     ---     ---
   Bleeding                          1                1/40                      1/36              0.90 (0.06--13.87)   0.940     ---     ---     ---
   Stomach discomfort                1                2/55                      4/55              0.50 (0.10--2.62)    0.653     ---     ---     ---
  Unstable angina                                                                                                                                 
   Total heart events                7                36/337                    78/333            0.46 (0.32--0.66)    \<0.001   1.15    0.979   0.0
   Death                             1                0/40                      2/38              0.19 (0.01--3.84)    0.279     ---     ---     ---
   Myocardial infarction             19               33/775                    92/741            0.37 (0.26--0.54)    \<0.001   14.32   0.708   0.0
   Cardiac arrhythmia                1                5/50                      10/50             0.50 (0.18--1.36)    0.174     ---     ---     ---
   Heart failure                     2                5/80                      12/77             0.41 (0.15--1.09)    0.075     0.10    0.754   0.0
   Angina                            12               40/585                    99/533            0.36 (0.26--0.51)    \<0.001   7.79    0.732   0.0
   Fatal events                      4                0/147                     4/147             0.33 (0.07--1.62)    0.173     0.00    1.000   0.0
   Sudden cardiac death              5                0/243                     9/243             0.22 (0.06--0.84)    0.027     0.08    0.999   0.0
   Cardiac surgery                   2                2/56                      7/56              0.29 (0.06--1.32)    0.108     0.33    0.564   0.0
   PCI                               3                3/118                     9/117             0.35 (0.11--1.16)    0.088     0.96    0.618   0.0
   Bleeding                          1                1/31                      11/31             0.09 (0.01--0.66)    0.018     ---     ---     ---
   Stomach discomfort                2                1/63                      3/63              0.67 (0.11--3.90)    0.653     1.49    0.222   32.8
  Stable angina or unstable angina                                                                                                                
   Total heart events                1                3/39                      7/39              0.43 (0.12--1.54)    0.194     ---     ---     ---
   Death                             2                6/173                     11/202            0.58 (0.23--1.48)    0.256     0.32    0.570   0.0
   Myocardial infarction             4                10/320                    31/348            0.34 (0.17--0.68)    0.002     0.46    0.984   0.0
   Cardiac arrhythmia                1                2/30                      4/30              0.50 (0.10--2.53)    0.402     ---     ---     ---
   Heart failure                     2                12/110                    26/109            0.46 (0.24--0.86)    0.015     0.21    0.646   0.0
   Angina                            4                25/210                    54/208            0.46 (0.30--0.70)    \<0.001   0.70    0.874   0.0
   Fatal events                      2                4/110                     9/109             0.44 (0.14--1.39)    0.161     0.01    0.903   0.0
   Sudden cardiac death              1                1/61                      3/60              0.33 (0.04--3.06)    0.328     ---     ---     ---
   Cardiac operation                 1                8/80                      16/79             0.49 (0.22--1.09)    0.080     ---     ---     ---
   Bleeding                          1                1/40                      1/36              0.90 (0.06--13.87)   0.940     ---     ---     ---
   Stomach discomfort                3                8/130                     2/129             2.99 (0.83--10.73)   0.094     1.04    0.594   0.0

CHM: chinese herbal medicine; RR: risk ratio; CI: confidence interval; PCI: percutaneous transluminal coronary intervention.

[^1]: Academic Editor: Lixing Lao
